Reconstitution of the type II [3H]estradiol binding site with recombinant histone H4

Journal of Steroid Biochemistry and Molecular Biology

Volumn 99, Issue 1, 2006, Pages 1-8

  Shoulars, Kevin ^a   Rodriguez, Mary Ann ^a   Crowley, Jan ^c   Turk, John ^c   Thompson, Trellis ^a   Markaverich, Barry M ^a,b  

^a Department of Molecular and Cellular Biology ^*  (United States)

^b University Center for Pain Medicine   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioflavonoid; Histone H4; Luteolin; Methyl p hydroxyphenyllactate (MeHPLA); Recombinant protein; Type II 3H estradiol binding site

Indexed keywords

BIOFLAVONOID; ESTRADIOL; HISTONE H3; HISTONE H4; LUTEOLIN; METHYL 4 HYDROXYPHENYLLACTATE; RECOMBINANT PROTEIN; TRITIUM; UNCLASSIFIED DRUG; HISTONE;

ARTICLE; BINDING ASSAY; BINDING SITE; CELL PROLIFERATION; EPIGENETICS; GENE EXPRESSION; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; SCATCHARD PLOT; UTERUS; AMINO ACID SEQUENCE; ANIMAL; BIOSYNTHESIS; ESCHERICHIA COLI; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MOLECULAR GENETICS; RAT;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; ESCHERICHIA COLI; ESTRADIOL; HISTONES; MOLECULAR SEQUENCE DATA; RATS; RECOMBINANT PROTEINS; TRITIUM;

EID: 33745175535     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.11.009     Document Type: Article

References (33)

1. Eriksson H.A., Hardin J.W., Markaverich B., Upchurch S., and Clark J.H. Estrogen binding in the rat uterus: heterogeneity of sites and relation to uterotrophic response. J. Steroid Biochem. 12 (1980) 121-130
2. Markaverich B.M., and Clark J.H. Two binding sites for estradiol in rat uterine nuclei: relationship to uterotropic response. Endocrinology 105 6 (1979) 1458-1462
3. Clark J.H., Markaverich B., Upchurch S., Eriksson H., Hardin J.W., and Peck Jr. E.J. Heterogeneity of estrogen binding sites: relationship to estrogen receptors and estrogen responses. Recent Prog. Horm. Res. 36 (1980) 89-134
4. Markaverich B.M., and Gregory R.R. Preliminary characterization and partial purification of rat uterine nuclear type II binding sites. Biochem. Biophys. Res. Commun. 177 3 (1991) 1283-1290
5. Markaverich B.M., Schauweker T.H., Gregory R.R., Varma M., Kittrell F.S., Medina D., and Varma R.S. Nuclear type II sites and malignant cell proliferation: inhibition by 2,6-bis-benzylidenecyclohexanones. Cancer Res. 52 9 (1992) 2482-2488
6. Piantelli M., Maggiano N., Ricci R., Larocca L.M., Capelli A., Scambia G., Isola G., Natali P.G., and Ranelletti F.O. Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J. Invest. Dermatol. 105 2 (1995) 248-253
7. Piantelli M., Ricci R., Larocca L.M., Rinelli A., Capelli A., Rizzo S., Scambia G., and Ranelletti F.O. Type II oestrogen binding sites in human colorectal carcinoma. J. Clin. Pathol. 43 12 (1990) 1004-1006
8. Markaverich B.M., Roberts R.R., Alejandro M.A., Johnson G.A., Middleditch B.S., and Clark J.H. Bioflavonoid interaction with rat uterine type II binding sites and cell growth inhibition. J. Steroid Biochem. 30 1-6 (1988) 71-78
9. Markaverich B.M., Gregory R.R., Alejandro M.A., Clark J.H., Johnson G.A., and Middleditch B.S. Methyl p-hydroxyphenyllactate. An inhibitor of cell growth and proliferation and an endogenous ligand for nuclear type-II binding sites. J. Biol. Chem. 263 15 (1988) 7203-7210
10. Markaverich B.M., Roberts R.R., Finney R.W., and Clark J.H. Preliminary characterization of an endogenous inhibitor of [3H]estradiol binding in rat uterine nuclei. J. Biol. Chem. 258 19 (1983) 11663-11671
11. Markaverich B.M., Gregory R.R., Alejandro M., Kittrell F.S., Medina D., Clark J.H., Varma M., and Varma R.S. Methyl p-hydroxyphenyllactate and nuclear type II binding sites in malignant cells: metabolic fate and mammary tumor growth. Cancer Res. 50 5 (1990) 1470-1478
12. Markaverich B.M., Gregory R.R., Alejandro M.A., Varma R.S., Johnson G.A., and Middleditch B.S. Estrogen regulation of methyl p-hydroxyphenyllactate hydrolysis: correlation with estrogen stimulation of rat uterine growth. J. Steroid Biochem. 33 5 (1989) 867-876
13. Markaverich B.M., and Gregory R.R. Preliminary assessment of luteolin as an affinity ligand for type II estrogen-binding sites in rat uterine nuclear extracts. Steroids 58 6 (1993) 268-274
14. Markaverich B., Shoulars K., and Alejandro M. Nuclear type II [3H]estradiol binding site ligands: inhibition of MCF-7 breast cancer cell proliferation and cMyc and cyclin D1 gene expression. Cancer Res. (2005)
15. Markaverich B.M., Shoulars K., and Brown M.A. Purification and characterization of nuclear type II [(3)H]estradiol binding sites from the rat uterus: covalent labeling with [(3)H]luteolin. Steroids 66 9 (2001) 707-719
16. Shoulars K., Brown T., Alejandro M.A., Crowley J., and Markaverich B.M. Identification of nuclear type II [(3)H]estradiol binding sites as histone H4. Biochem. Biophys. Res. Commun. 296 5 (2002) 1083-1090
17. Shoulars K., Rodrigues M.A., Crowley J.R., Turk J., Thompson T., and Markaverich B.M. Nuclear type II [(3)H]estradiol binding sites: A histone H3-H4 complex. J. Steroid Biochem. Mol. Biol. 96 1 (2005) 19-30
18. Tanaka Y., Tawaramoto-Sasanuma M., Kawaguchi S., Ohta T., Yoda K., Kurumizaka H., and Yokoyama S. Expression and purification of recombinant human histones. Methods 33 1 (2004) 3-11
19. Markaverich B.M., Adams N.R., Roberts R.R., Alejandro M., and Clark J.H. Cytosol type II sites in the rat uterus: interaction with an endogenous ligand. J. Steroid Biochem. 28 6 (1987) 599-608
20. Clark J.H., Markaverich B., Upchurch S., Eriksson H., and Hardin J.W. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response. Adv. Exp. Med. Biol. 117 (1979) 17-46
21. Syne J.S., Markaverich B.M., Clark J.H., and Panko W.B. Estrogen binding sites in the nucleus of normal and malignant human tissue: optimization of an exchange assay for the measurement of specific binding. Cancer Res. 42 11 (1982) 4443-4448
22. Markaverich B.M., Williams M., Upchurch S., and Clark J.H. Heterogeneity of nuclear estrogen-binding sites in the rat uterus: a simple method for the quantitation of type I and type II sites by [3H]estradiol exchange. Endocrinology 109 1 (1981) 62-69
23. Markaverich B.M., Roberts R.R., Alejandro M.A., and Clark J.H. Uterine type II estrogen-binding sites are not of eosinophil origin. J. Biol. Chem. 261 1 (1986) 142-146
24. Densmore C.L., Schauweker T.H., Gregory R.R., Webb B., Garcia E., and Markaverich B.M. Chromatographic resolution of the type II estrogen binding site and a tyrosinase-like enzymatic activity from rat uterine nuclei. Steroids 59 4 (1994) 282-287
25. Garai J., and Adlercreutz H. Estrogen-inducible uterine flavonoid binding sites: is it time to reconsider?. J. Steroid Biochem. Mol. Biol. 88 4/5 (2004) 377-381
26. Cheung P., Allis C., and Sassone-Corsi P. Signaling to chromatin through histone modifications. Cell 103 (2000) 263-271
27. Fischle W., Wang Y., and Allis C.D. Histone and chromatin cross-talk. Curr. Opin. Cell Biol. 15 2 (2003) 172-183
28. Klochendler-Yeivin A., and Yaniv M. Chromatin modifiers and tumor suppression. Biochim. Biophys. Acta 1551 1 (2001) M1-M10
29. Archer S.Y., and Hodin R.A. Histone acetylation and cancer. Curr. Opin. Genet. Dev. 9 2 (1999) 171-174
30. Wang Y., Fischle W., Cheung W., Jacobs S., Khorasanizadeh S., and Allis C.D. Beyond the double helix: writing and reading the histone code. Novartis Found Symp. 259 (2004) 3-17 (Discussion 17-21, 163-169)
31. Frank S.R., Schroeder M., Fernandez P., Taubert S., and Amati B. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 15 16 (2001) 2069-2082
32. Jenuwein T., and Allis C.D. Translating the histone code. Science 293 5532 (2001) 1074-1080
33. Das P.M., and Singal R. DNA methylation and cancer. J. Clin. Oncol. 22 22 (2004) 4632-4642